Idera Pharmaceuticals Reports First Quarter 2021 Financial Results
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) recently reported its financial and operational results for the first quarter ended March 31, 2021.
Read MoreIdera Pharmaceuticals
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), headquartered in Exton, PA, is a clinical-stage biotechnology company focused on taking the next step in immuno-oncology therapies.
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory …
Read More Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) has reported its financial and operational results for the fourth quarter and year ended December 31, 2020.
Read More Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced the closing of a second tranche under its April 7, 2020, securities purchase agreement, resulting in aggregate proceeds of up to …
Read More Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that Daniel Soland will join Idera on January 4, 2021, as Senior Vice President and Chief Operating Officer (COO). Mr. Soland …
Read More Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) reported its financial and operational results for the third quarter ended September 30, 2020.
Read More Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907 Patent) and allowed U.S. Patent Application …
Read More Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that final data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented in …
Read More Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) reported its financial and operational results for the second quarter ended June 30, 2020.
Read More Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced entering into an agreement with a fund affiliated with institutional investors providing for a private placement exempt from the registration requirements …
Read More